CO6270355A2 - Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa - Google Patents

Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa

Info

Publication number
CO6270355A2
CO6270355A2 CO10051575A CO10051575A CO6270355A2 CO 6270355 A2 CO6270355 A2 CO 6270355A2 CO 10051575 A CO10051575 A CO 10051575A CO 10051575 A CO10051575 A CO 10051575A CO 6270355 A2 CO6270355 A2 CO 6270355A2
Authority
CO
Colombia
Prior art keywords
pentanoic acid
secretase
aromatic derivatives
modulation activity
obtain aromatic
Prior art date
Application number
CO10051575A
Other languages
English (en)
Inventor
Chih Yung Ho
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6270355A2 publication Critical patent/CO6270355A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se relaciona con el uso de los compuestos que tienen la Formula general I, en donde las definiciones o R1 y R2 son proporcionadas en la especificacion. Dichos compuestos de la Formula I son ·tiles para la sintesis de una variedad de moduladores de la ?-secretasa, los que a su vez son ·tiles para el tratamiento de las enfermedades asociadas con la actividad de la ?-secretasa, incluso la enfermedad de Alzheimer.
CO10051575A 2007-10-19 2010-04-30 Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa CO6270355A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98125707P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6270355A2 true CO6270355A2 (es) 2011-04-20

Family

ID=40092042

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10051575A CO6270355A2 (es) 2007-10-19 2010-04-30 Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa

Country Status (16)

Country Link
US (1) US20090306392A1 (es)
EP (1) EP2209764A1 (es)
JP (1) JP2011500720A (es)
KR (1) KR20100081350A (es)
CN (1) CN101903334A (es)
AU (1) AU2008312362A1 (es)
BR (1) BRPI0817789A2 (es)
CA (1) CA2702911A1 (es)
CO (1) CO6270355A2 (es)
CR (1) CR11449A (es)
EA (1) EA201070497A1 (es)
IL (1) IL205040A0 (es)
MX (1) MX2010004311A (es)
NI (1) NI201000067A (es)
WO (1) WO2009052341A1 (es)
ZA (1) ZA201003521B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019710B1 (ru) * 2007-10-19 2014-05-30 Янссен Фармацевтика, Н.В. ПРОИЗВОДНЫЕ 2-АРИЛ-4-МЕТИЛПЕНТАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ γ-СЕКРЕТАЗЫ
ES2378594T3 (es) * 2007-10-19 2012-04-16 Janssen Pharmaceutica, N.V. Moduladores de piperidinilo y piperazinilo de la y-secretasa
WO2009052350A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
CN105646452B (zh) * 2015-12-24 2018-05-01 北京康立生医药技术开发有限公司 一种蛋白激酶抑制剂的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
EP1847524B1 (en) * 2006-04-21 2009-10-14 Cellzome Limited Terphenyl derivatives for treatment of Alzheimer's disease
PL1849762T3 (pl) * 2006-04-21 2009-12-31 Cellzome Ltd Podstawione kwasy bifenylo-karboksylowe i ich pochodne

Also Published As

Publication number Publication date
ZA201003521B (en) 2011-08-31
US20090306392A1 (en) 2009-12-10
EP2209764A1 (en) 2010-07-28
CA2702911A1 (en) 2009-04-23
BRPI0817789A2 (pt) 2015-03-24
KR20100081350A (ko) 2010-07-14
JP2011500720A (ja) 2011-01-06
WO2009052341A1 (en) 2009-04-23
MX2010004311A (es) 2010-05-03
EA201070497A1 (ru) 2010-12-30
AU2008312362A1 (en) 2009-04-23
AU2008312362A2 (en) 2010-07-08
CR11449A (es) 2011-01-14
IL205040A0 (en) 2010-11-30
CN101903334A (zh) 2010-12-01
NI201000067A (es) 2010-09-13

Similar Documents

Publication Publication Date Title
AR051577A1 (es) Derivados eter sustituidos por hexafluorisopropanol
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY30500A1 (es) Compuestos de azabencimidazolilo
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CY1112298T1 (el) Ενωσεις και μεθοδοι για ρυθμιση fxr
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
CR9507A (es) Sulfonamidas de diarisulfona y sus usos
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CR10376A (es) Derivados de terfenil para el tratamiento de la enfermedad de alzheimer
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CO6270355A2 (es) Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa
GT200700097A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
CO6280529A2 (es) DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA
CO6280527A2 (es) Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa
UY30550A1 (es) Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
FA Application withdrawn